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Abstract: This overview describes the nature of the immune responses
induced by the inhalation of allergens. There is a dichotomy in that B
cells have multiple mechanisms that limit the amount of immuno-
globulin E (IgE) antibody production, whereas T-cell responses are
large even in nonallergic subjects. With the possible exception of
responses to cat allergen, however, T cells from nonallergic subjects
have limited effector function of helping IgG antibody, and in house-
dust mite allergy, this declines with age. Regulation by interleukin 10
(IL-10)Yproducing cells and CD25+ T-regulatory cells has been
proposed, but critically, there is limited evidence for this, and many
studies show the highest IL-10 production by cells from allergic
subjects. Recent studies have shown the importance of nonlymphoid
chemokines thymic stromal lymphopoietin and IL-27, so studying
responses in situ is critical. Most sources of allergens have 1 or 2
dominant allergens, and for house-dust mite, it has been shown that
people have a predictable responsiveness to highY, midY and poorYIgE-
binding proteins regardless of the total size of their response. This
allergen hierarchy can be used to design improved allergen preparations
and to investigate how antiallergen responses are regulated.
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IMMUNOGLOBULIN E RESPONSES TO
ALLERGENS
A hallmark of immediate hypersensitivity is the ability of
mast cells and basophils armed with small amounts of
immunoglobulin E (IgE) antibody to induce powerful inﬂam-
matory reactions. Immunoglobulin E is indeed produced in
lower amounts than themore common IgG isotypes. The serum
immunoglobulin levels, which vary with atopic status, are in
the region of 5 to 500 ng/mL compared with 0.5 and 10 mg/mL
of IgG4 and IgG1, respectively. There are few IgE-producing
cells, and IgE has a short half-life. Recent studies show that the
IgE antibody titers in humans correlate very well with the
presence of IgE producing early plasma cells in the blood,1
suggesting that the IgE response is predominantly caused by
short-lived cells, and this is compatible with the diminution of
IgE antipollen titers found between pollen seasons. There are at
least 2 control points at the molecular level. The rate of
translocation of the Vh genes to the 0 gene in class switching is
intrinsically weak compared with the switching for gamma
subclasses,2 and RNA transcripts for membrane IgE are
unstable compared with the IgG counterparts.3 At the cellular
level, it has been shown in mice that B cells with surface IgE
are exceptional because they were largely found outside
germinal centers.4 They arise from a pre-IgE phase, where
somatic mutation and afﬁnity maturation take place in IgG1+
cells, and a postYIgE-switching phase, in which IgE cells
differentiate swiftly into plasma cells. This leaves a deﬁciency
in IgE-bearing memory cells that would maintain long-lived
responses. Studies on the immunoglobulin heavy chain
repertoire expressed by antiallergen IgE antibodies show
that there are no restrictions with respect to the macroele-
ments of repertoire diversiﬁcation such as the selection of Vh
gene families or VDJ recombinations,5 but that the responses
show a lower repertoire with respect to the number of
different Vh genes. Selection from continued exposure to low
doses of antigen or limitations of antigen binding imposed by
the unique structure of IgE could account for this. For the last
possibility, it has been proposed that steric hindrance of
antigen binding might occur because IgE has a bent structure
that places the Vh region in close proximity to the C-terminal
of the constant region.6
Consistent with tight control mechanisms, it has been
repeatedly demonstrated that antiallergen antibodies constitute
a large portion of the IgE immunoglobulin.7Y9 The size of the
average IgE antibody response varies with the nature of the
allergen source. The serum concentration of IgE antibody
binding to the dominant allergens of birch,10 grass,11 and
mite12,13 are about 50 ng/mL, whereas Amb a 1 has been
reported as 20 ng/mL,14 and the cockroach Bla g 2 and 5 have
a combined average of 10 ng/mL.15 Many people have low
levels of IgE to cat,16,17 so the average anti-Fel d 1 levels are
about 4 ng/mL. Some people, however, have very high levels,
with more than 100 ng/mL.18 The Can f 1 dog allergen has
comparable IgE titers to Fel d 1, but only a small sample of
subjects has been examined.16 Immunoglobulin E antibodies
to the mouse allergen Mus m 1 are also present in small
quantities, with an average of about 1 ng/mL in subjects that
develop disease after domestic and industrial exposure.19
There is a possibility that lower evolutionary divergence
contributes to lower responses to mammalian allergens, but
given that Fel d 1 only has 20% identity with the human
uteroglobin homologue, other factors such as the aerody-
namics of the allergen may be involved.
The engagement of IgE with the high-afﬁnity Fc?R1 in
the absence of allergen increases the expression of the receptor
on the surface of basophils, mast cells, and dendritic cells, so
that the IgE levels, and thus the type of allergen-inducing sen-
sitization, can directly affect the allergic response. It was thought
that this occurred by inducing the synthesis of Fc?R1, but it now
seems to occur via a membrane-stabilizing process.20
REVIEW ARTICLE
WAO Journal & June 2008 89
Received for publication January 15, 2008; accepted April 1, 2008.
From the Centre for Child Health Research, University of Western Australia,
Telethon Institute for Health Research, Western Australia.
Supported by the National Health and Medical Research Council of Australia.
Reprints: Wayne R. Thomas, Centre for Child Health Research, University of
Western Australia, Telethon Institute for Health Research, 100 Roberts Rd,
Subiaco 6008, Western Australia. E-mail: wayne@ichr.uwa.edu.au
Copyright * 2008 by World Allergy Organization
The development of allergic symptoms is related to the
titers of antiallergen IgE antibody, but even children with the
highest titers only have a 60% probability of disease as shown
for wheeze in asthma, and although the probability declined
with reduced titers, it was still elevated at the low level of 4.4
ng/mL.21 The classiﬁcation of the disease must also be
considered. In house dust mite (HDM) allergy, for example,
only children with the highest IgE antibody titers have
persistent asthma,22 a very severe form of the disease.
Exacerbation of intermittent asthma for example by infection
is a more frequent health problem, producing 75% of hospital
admissions for asthma in children,23 and many such children
with mite-allergy have quite low titers, less than 10 ng/mL.13
T-CELL RESPONSES
In contrast to IgE antibody, the T-cell responses to allergens
are large. The precursor frequencies of T cells responding to
allergen extracts have been reported for pollen24 and HDM
allergy.25,26 For mites, the frequencies of T-cell precursors in the
peripheral blood were in the range of 0.05% to 0.1% for allergic
subjects and 0.01% to 0.02% for nonallergic subjects. Subjects
allergic to birch and grass pollen had precursor frequencies
with an average of 0.56% for symptomatic subjects and 0.12%
for nonallergic nonatopic people. Assing et al24 also determined
the precursor frequencies in people who had skin test reactions
but were asymptomatic, ﬁnding a frequency of 0.13%, being
the same as skin testYnegative controls. The asymptomatic skin
testYpositive people, however, had low levels of IgE antibody
and skin test reactivity compared with the symptomatic sub-
jects, so this does not provide information on why some subjects
with high levels of sensitization have few symptoms. For
comparison with allergens, frequencies in the region of 0.001%
for KLH27 Leishmania28 and hepatitis B29 have been found
before immunization and rise to about 0.02% after vaccinations.
Thus, even nonallergic subjects show a large degree of ex-
pansion. The allergen-responsive T cells of allergic subjects
are mainly in the memory CD45RO+ population24,25 compart-
ment, whereas allergen-responsive cells are found in both the
CD45RO+ and CD45RA+ compartments of nonallergic sub-
jects.25 The induction of the Th2 transcription factor GATA-3 by
HDM extract has also been shown to be stronger in CD45RO+
cells.30
Although most of the T-cell responses in allergy have
been studied with extracts, the use of puriﬁed allergens is more
informative because the stimulating speciﬁcities and the con-
centration used is known and can be accounted for. The T-cell
responses to the dominant allergens from grass pollen,31,32
birch,33 weeds,34,35 mite,36 and cat37 have been studied. The
proliferative responses induced in the peripheral blood
mononuclear cells (PBMCs) from allergic people are generally
better than those of cells from nonallergic people, although
there is considerable overlap.36 The induction of the Th2 cyto-
kines interleukin 5 (IL-5) and IL-13 can be readily detected,38Y40
although IL-4 is typically produced in low amounts. Contrary to
early observations with extended T-cell culture, PBMCs from
allergic subjects show the same amount of interferon-F (IFN-F)
release as cells from nonallergic subjects as demonstrated with
mite38Y41and pollen allergens.24,41,42 Some studies have even
shown increased IFN-F.43Y45 The amount of IFN-F induced by
allergens is very similar to that reported to be induced by Th1-
type bacterial antigens and vaccines,46Y48 so they are not trivial
responses. It is likely that the early observations of low IFN-F
from allergic subjects were caused by the potent inhibitory
activity of IL-4 on Th1 responses in culture. An interesting
observation of Assing et al49 was that IL-2 was released in excess
in cultures of PBMCs from symptomatic pollen-sensitized
people and could not be detected in nonsymptomatic and skin
testYnegative people. Not only is IL-2 produced in larger
amounts by Th1 cells, but it is also important for the induction
of regulatory T cells.
CD4+ cells have been shown to be the predominant
source of Th2 cytokines in PBMCs50 and to predominate in
the cellular inﬁltrates of airways.51 The Der p 1 allergen has,
however, also been shown to stimulate the release of IFN-F
from CD8+ cells although in in vitro cultures, provided that
they were supplemented with IL-2.43 In a later article, Der
p1-speciﬁc CD8 cells were detected by isolating T cells with
a major histocompatibility complex class I binding peptide
tetramer.52
Studies on cytokine production in situ have shown that
the Th2 polarization is best found in the lungs and not the
peripheral blood.53 Thymic stromal lymphopoietin (TSLP)
could have a large effect in the target organ. This epithelial
cell product,54 presumably stimulated by tissue damage, is
a powerful inducer of Th2 responses, mediating both expansion
and polarization while maintaining the central T-cell memory.55
It is in turn stimulated by Th2 cytokines and TNF-> and shown to
be unaffected by IL-10, IFN-F, and transforming growth
factor-A (TGF-A). Recent studies have identiﬁed that T-cell
receptorYactivated T cells express the TSLP receptor, thus
providing a marker for the allergy-mediating cells.56 This
would permit a direct action on T cells as well as the previously
known effect via the dendritic cells. The IL-27 secreted by
macrophages and dendritic cells may have a reciprocal role,
having a potent suppressive action on Th2 as well as Th17
responses.57 The cytokine bias of T cells in vivo can be tracked
to some extent by their chemokine receptors. The Th2 cells
preferentially express the chemokine receptors CCR3, CCR4,
and CCR8 and migrate to their respective ligands, eotaxin
(CCL11), monocyte-derived chemokine (MDC) (CCL22) and
thymus- and activation-regulated chemokine (TARC)
(CCL17). Bronchial lavages of asthmatic subjects show the
accumulation of CCR4+ CD4+ cells and the secretions of the
corresponding chemokines TARC andMDC.58 Endobronchial
biopsies after allergen challenge revealed that most of the
inﬁltrating T cells expressed CCR4 with some coexpression of
CCR8, and the epithelial cells produced MDC and TARC.59,60
The Th1-type IP-10 chemokine can also be produced in
asthma, as shown by its production after segmental lung
challenges with ragweed, HDM, and cat extracts.61,62 Patients
who produced late-phase reactions to allergen challenge
produce more of both the Th1 and Th2 chemokines.61
The chemokine receptor bias of allergen-responsive
T cells to CCR4 has also been detected in grass pollen
allergy.24,63 The PBMCs of allergic subjects also preferentially
produce the corresponding Th2 TARC and MDC compared
with cells from nonallergic people.64,65 Recently, pollen
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allergenYresponsive CCR4 cells have been shown to be
increased in the pollen season and to be associated with the
increased CD62L CD45RO markers for central memory.66
Allergen-stimulated cells can also be tracked ex vivo by
tetramer-binding cells. A study of CD4+ T cells from atopic
dermatitis patients with IgE antibody to the cat allergen Fel d 1
used tetramer binding to show a similar result, with most of the
T cells being within the central memory compartment.67 Their
frequency was about 0.01% for cells from atopic dermatitis
patients and about 0.002% for cells from nonallergic people.
Both of these are also high, considering that only 1 epitope
bound to 1 HLA-DR molecule was measured. Cat exposure
was not reported.
REGULATORY T-CELL RESPONSES
There are many observations that show that patients
undergoing immunotherapy produce more IL-10 and TGF-
A,68 but it is not clear if these regulators have any control over
the development of allergic sensitization. There is consider-
able signiﬁcance given to the report by Akdis et al,41 showing
that Der p 1 and pollen allergenYstimulated cells from every
nonallergic person examined produced more IL-10 than cells
from every allergic person examined. Clear-cut results have
not been obtained by other studies. A nonsigniﬁcant trend for
less IL-10 production by cells from symptomatic cat- and
pollen-sensitive children has been reported,69 but most studies
have found that IL-10 is produced in higher amounts by cells
from allergic subjects. This has been shown for puriﬁed HDM
allergens40,45,70 and for cells stimulated with cat and pollen
extracts.49,71,72 A study with pure Fel d 1 found that cells from
cat-allergic and nonallergic subjects produced the same
amount of IL-10,37 and the latter included people producing
IgG4 antibodies. A recent study of Bet v 1 stimulation in birch
pollen allergy showed no difference in the IL-10 release
induced in cells from allergic and nonallergic subjects,42 as
previously reported by Bullens et al.73 Bullens et al73 also
found similar levels of IL-10 induced by Der p 2 stimulation.74
Increased IL-10 has also been found in bronchial and skin
challenge sites of HDM allergic people, as indicated by
messenger RNA transcription.75
Evidence that IL-10 might regulate the responses of
cells from healthy individuals has been obtained by experi-
ments where the addition of antiYIL-10 receptor antibodies to
cultures of their PBMCs enhanced proliferative responses to
Der p 1.76 This observation was not reproduced in the study
with Bet v 1,42 although antiYIL-10 did increase the
production of IFN-F and TNF-> but not Th2 cytokines. The
possibility of a regulatory role for IL-10 in allergic subjects
has been indicated in HDM allergy, where patients who
produce more IL-10 had smaller wheal sizes in skin prick
tests.45,70 Opposite to this, however, has been the demonstra-
tion that children with early and persistent allergy have more
disease and higher Th2 cytokine responses than children with
late-onset allergy and that they also have higher IL-10
responses.77
Suppressive effects of CD4+CD25+ T-regulatory cells
have been demonstrated on the proliferation responses of
PBMCs cultured with cat and pollen allergens. There was,
however, no convincing difference in the activity of cells from
allergic and nonallergic subjects78,79 or the inhibition of
effector events such as cytokine production. The study of Ling
et al78 did show decreased suppression within the pollen
season, but because the T-cell responses were much higher
than outside of the season, the effect is difﬁcult to interpret. A
study of birch allergy outside of the pollen season found that
although nonallergic subjects and patients tended to have
reduced IL-10 release from the CD25+ cells, it was possible to
detect a suppressive activity on T-cell proliferation for the cells
from allergic, but not nonallergic, subjects.42 Inspection of the
data, however, suggests that this was caused by uncharacter-
istically low proliferative responses of the cells from allergic
subjects and a higher proliferation of the CD25+ population
itself. The Th2 cytokine responses were not affected by the
presence of CD25+ cells. Studies of atopic dermatitis showed
that HDM extract stimulated more of the regulatory cell
transcription factor FOXP3 from PBMCs from HDM-allergic
subjects than PBMCs from nonallergic subjects,80 and that
pollen-allergic children have increased numbers of CD4+
CD25+ cells.81 Studies of T-regulatory cells are, however,
clouded by the knowledge that both CD25 and FOXP3 are
induced in activated effector and regulatory T cells, albeit
transiently.82 CD4+CD25+ high or bright cells are considered
to have high regulatory activity, with few or no effector T cells.
However, the CD4+CD25+ high subgroup has been shown to
contain a mixture of both regulatory and effector T cells, and
the percentage of CD4+CD25 high T cells correlated
negatively with the suppressive capacity of CD4+CD25+ T
cells.81 There is an absolute requirement for TGF-A in the
development of T-regulatory cells, and the ability of a TGF-A
antagonist to increase T-cell proliferative responses to Der p 1
has been reported.76 Although the experimental studies to date
have been inconclusive, an overall role of T-regulatory cells is




There is good agreement that IgG antibodies to grass,84
ragweed,85 mite,13,70,86 and birch87 allergens are predomi-
nantly found in sera of people with IgE antibodies. It therefore
appears that although nonsensitized people have T-cell
responses to these allergens, they do not make antibody
responses of signiﬁcant magnitude. For mites, some studies
with mite extracts have reported pan IgG in nonallergic
subjects, but this is difﬁcult to measure, and the method of
differentiating from nonspeciﬁc binding was not given.88 Not
all allergic people produce IgG, with Hales et al13 ﬁnding IgG
in 70% of mite-allergic children but only in 40% of adults.
Furthermore, only 25% of children admitted to an emergency
department had IgG and the titers were low, suggesting a
relationship with susceptibility to exacerbation.13 Jarvis et al88
reported an association of IgG4 with symptoms in adults, but
this analysis only measured the general association of IgG
found in sensitized subjects. The titers of antibodies to the
major HDM allergens reach about 0.5 Kg/mL for IgG4 and 10
Kg/mL for IgG1. These titers are similar to the antibody titers
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found to a Haemophilus inﬂuenzae P6 protein antigen using
the same technique and other antibacterial responses.89,90
They are however lower than levels that would induce
antibody-mediated pneumonitis.91 Cockroach IgG antibodies
are mainly also associated with IgE responses.15 Grass pollen
allergens induce lower IgG antibody titers than mite with
mainly IgG4 antibodies at less than 1 Kg/mL.92
Fel d 1 has been reported to induce IgG antibodies in
most people exposed to cats93 possibly because it is present in
inhalable air in 50- to 100-fold higher concentrations than mite
and pollen allergens.94 It has been proposed that this tolerizes
for IgE while maintaining IgG production.93 A recent study,
however, found that IgG antibodies to cat were 10-fold higher
in people with IgE.88 Mouse allergens have also been reported
to induce IgG in nonallergic people in studies of occupational
exposure,95 but data from domestic exposure showed a strong
association of IgG antibody with IgE. This may be related to
the 50 times lower amounts of Mus m 1 in the air of homes
compared with Fel d 1.95
ANTI-HDM RESPONSES ARE HIERARCHICAL
Most of the IgE binding to the common sources of
allergen is directed to a small number of dominant allergens.
Bet v 1 is a very dominant allergen binding 90% of the IgE
antibodies to birch pollen in sera from people in Scandina-
via.96 Ole e 1 has a similar dominance for olive pollen,97 and
the group 1 and 5 allergens from grass pollen allergens
collectively bind 80% of the IgE in 95% of sera.11 Amb a 1 is
the dominant allergen for ragweed, binding a range from 25%
to 85% of the IgE antibodies to pollen extracts.14 Immuno-
globulin E antibodies to Fel d 1 constitute about 50% of the
IgE binding to cat dander extracts,18 although this may not be
the major source of all cat allergens.17 The combination of the
group 1 and 2 HDM allergens binds over 50% of the antimite
antibodies.12,13
To examine the relative binding of the nonmajor mite
allergens to the known major Der p 1 and Der p 2 allergens, a
panel of 9 allergens was prepared including allergens known to
absorb out the IgE binding to nearly all the allergens detectable
by IgE immunoblotting of 2-dimensional electrophoresed
extracts.98 The allergens used were either natural allergens or
recombinant allergens whose structure had been validated by
biochemical function or allergenicity. All the antiallergen
antibody measurements were conducted in standardized
conditions, so the titers were not inﬂuenced by the amount
of allergen.13 There was an excellent correlation of the
summated titers of IgE to the different allergens with the
values obtained by the Phadebas CAP system with mite
extract. Immunoglobulin E antibodies to Der p 1 and 2 made
up about 50% of the binding, regardless of the size of the total
response or the presence of symptoms. Immunoglobulin E
binding to Der p 4, 5, and 7 collectively accounted for 30% of
the IgE, and this varied in proportion to the titers to Der p 1
and 2. Binding to Der p 3, 8, 10, and 20 was quantitatively low
for nearly all people, although a high frequency of binding was
found for some of the allergens. The titers to the midpotency
Der p 4, 5, and 7 allergens of 10 ng/mL indicate that they
could be important. Comparison with other studies indicates
that IgE antibody titers to Der p 6, 9, 13, 16, and 17 will also
be very low.99 Immunoglobulin E binding therefore has a
hierarchy that is determined by the allergen. The ﬁnding that
there is the same hierarchy of response in low and high
responders means that different formulations to better
represent HDM allergens than extracts can be rationally
tested. The IgG antibody response to the allergens shows the
same hierarchy as the IgE binding, with the highest titer being
found to Der p 1 and 2 followed by Der p 4, 5, and 7. The same
mix of IgG1 and the highly Th2-dependent IgG4 antibodies
was found. There is at this stage no evidence for a
nonallergenic response to poor allergens. A caveat to this
study is that allergens of possible importance, namely Der p
11, 14, and 15 have not been studied because they have not
been produced or puriﬁed in the necessary amounts. The study
of the production of mite allergens has shown that poorly
allergenic molecules such as mite ferritin, the fatty acid
binding protein, tropomyosin, and arginine kinase are
produced in larger quantities than the major group 1 and 2
allergens and the midpotency group 4, 5, and 7 allergens.100
CONCLUSIONS
The IgE antibodies induced by allergens are produced in
low quantity, and because several features of the B-cell
response seem to contribute to this, the system seems tightly
regulated. In contrast, the precursor frequency and the amount
of cytokine produced by T cells responding to allergens are
high and of a similar magnitude to those found for
antimicrobial responses. They tend to be higher for allergic
compared with nonallergic people, but even the responses of
nonsensitized people are similar to those induced by vaccine
antigens. The IgG antibody titers are also higher in allergic
people, at least for responses to HDM, pollen, and cockroach
and mouse allergens. The titers to pollen are small, but the
magnitude of the responses to HDM allergens in children are
similar to antimicrobial responses and include the IgG1
isotype found in antimicrobial immunity and the highly Th2-
dependent IgG4 isotype. Only about 70% of children however
produce IgG, and the responses decline with age. It was also
found to be severely curtailed in children with intermittent
asthma experiencing acute exacerbations. The mechanisms
that regulate the IgG responses and perhaps the direct
inﬂuence of the presence of IgG could therefore be important
for disease. The lack of any antibody in nonallergic subjects
indicates an inefﬁcient helper T cell function, although allergic
and nonallergic subjects have good cytokine responses, as
shown by IFN-F release. The IFN-F responses of both allergic
and nonallergic people are similar and of a similar size to those
found in microbial antigens. It is becoming clear that
chemokine responses by nonlymphoid cells, especially
TSLP and possibly IL-27, are critical regulators of the allergic
response, so that responses studied in extended in vitro
cultures are not necessarily very informative. Regulatory
responses by IL-10Yproducing cells and CD25+ T-regulatory
cells have been proposed as important modiﬁers of the
responses of nonallergic subjects. It is however important to
note that the evidence for this is limited, and most studies show
that peripheral blood cells from allergic subjects produce more
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or similar amounts of IL-10 to the cells from nonallergic
subjects. This, however, could be the result of an interplay
between cytokines in the in vitro culture systems. At least
some people exposed to cats make high IgG4 responses to Fel
d 1 without the production of IgE antibody, and this could be
the result of a regulatory function. It is however possible that
the frequency at which this occurs is lower than previously
suspected. For HDM allergy, it has been shown that the IgE
and IgG responses induced by the different allergens are
hierarchical, with the proportion of the response directed to
each allergen being similar for all individuals. This not only
has use for designing improved allergen preparations, but also
can be used as an investigative tool for determining how the
responses are controlled.
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